Average Co-Inventor Count = 3.79
ph-index = 6
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Esbatech, an Alcon Biomedical Research Unit LLC (8 from 36 patents)
2. Telormedix Sa (4 from 6 patents)
3. Esbatech Ag (4 from 4 patents)
4. Delenex Therapeutics Ag (2 from 5 patents)
5. Novartis Ag (1 from 3,923 patents)
6. Urogen Pharma Ltd. (1 from 14 patents)
7. Cell Medica Switzerland Ag (1 from 5 patents)
8. Esbatech, an Alcon Boimedical Research Unit, LLC (1 from 1 patent)
9. Esbatech - a Novartis Company LLC (1 patent)
10. Oncalis Ag (0 patent)
22 patents:
1. 10570190 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
2. 10125186 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
3. 9683034 - Stable and soluble antibodies inhibiting TNFα
4. 9540407 - Phospholipid drug analogs
5. 9518108 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
6. 9512411 - Nucleic acid encoding antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
7. 9315572 - Stable and soluble antibodies inhibiting TNF alpha
8. 9180183 - Phospholipid drug analogs
9. 9173935 - Phospholipid drug analogs
10. 9173936 - Phospholipid drug analogs
11. 9050319 - Phospholipid drug analogs
12. 8945563 - Method for treating glioblastoma using antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
13. 8936785 - scFv antibodies which pass epithelial and/or endothelial layers
14. 8853362 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
15. 8691228 - Stable and soluble antibodies inhibiting TNFα